Table 2.
HBeAg(+) | HBeAg(−) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||
N | HBV-HIV | HBV only | Difference** | P | N | HBV-HIV | HBV only | Difference** | P | |
|
|
|||||||||
mean (95% CI) | mean (95% CI) | |||||||||
HBeAg (log10 IU/mL) | 112 | NA | NA | |||||||
| ||||||||||
Unadjusted | 1.00 (0.74-1.27) |
0.89 (0.60-1.18) |
0.12 (−0.27-0.51) |
0.55 | ||||||
| ||||||||||
Adjusted | 1.05 (0.45-1.66) |
0.51 (−0.19-1.22) |
0.54 (−0.01-1.08) |
0.051 | NA | |||||
HBsAg (log10 IU/mL) | 101 | 88 | ||||||||
| ||||||||||
Unadjusted | 3.49 (3.27-3.70) |
3.27 (2.93-3.61) |
0.21 (−0.18-0.61) |
0.28 | 2.41 (2.03-2.79) |
2.78 (2.46-3.09) |
−0.37 (−0.85-0.12) |
0.13 | ||
| ||||||||||
Adjusted | 3.85 (3.35-4.35) |
3.17 (2.48-3.86) |
0.68 (0.05-1.31) |
0.03 | 2.00 (1.18-2.82) |
3.04 (2.13-3.94) |
−1.04 (−1.69- −0.38) |
0.002 | ||
HBcrAg (log10 U/mL) | 116 | 94 | ||||||||
| ||||||||||
Unadjusted | 6.67 (6.23-7.11) |
6.25 (5.88-6.62) |
0.42 (−0.15-0.99) |
0.15 | 3.36 (2.86-3.86) |
2.80 (2.39-3.21) |
0.56 (−0.08-1.19) |
0.09 | ||
| ||||||||||
Adjusted | 6.59 (5.42-7.75) |
5.51 (4.24-6.79) |
1.08 (0.25-1.90) |
0.01 | 4.14 (3.14-5.15) |
3.64 (2.45-4.83) |
0.50 (−0.40-1.40) |
0.27 | ||
HBV RNA (log10 U/mL) | 116 | 94 | ||||||||
| ||||||||||
Unadjusted | 4.99 (4.62-5.36) |
4.33 (3.85-4.81) |
0.67 (0.07-1.27) |
0.03 | 1.63 (1.21-2.06) |
2.11 (1.75-2.47) |
−0.48 (−1.02-0.07) |
0.09 | ||
| ||||||||||
Adjusted | 5.60 (4.72-6.48) |
3.70 (2.66-4.73) |
1.90 (1.10-2.71) |
<.001 | 1.87 (0.95-2.78) |
2.66 (1.60-3.72) |
−0.80 (−1.59- −0.01) |
0.048 |
Acronyms: HBcrAg, Hepatitis B core-related antigen; HBeAg, Hepatitis B e antigen; HBsAg, Hepatitis B surface antigen; HBV, Hepatitis B virus; HIV, Human immunodeficiency virus; HBeAg, Hepatitis B e-antigen; NH, Non-Hispanic; RNA, Ribonucleic acid.
For age, sex (HBeAg+ models only), race (NH White, NH Black, NH Asian and other/missing), ALT category (≤1, >1-2, >2) and HBV DNA category (<20, 20-<1000, ≥1000-10000).
Mean (95%CI) difference in HBV-HIV co-infected versus HBV mono-infected participants.